Arrowhead (ARWR) announced that the Chinese National Medical Products Administration has approved Redemplo for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $85 from $50 at Goldman Sachs
- Arrowhead price target raised to $81 from $48 at Morgan Stanley
- Arrowhead price target raised to $80 from $60 at Chardan
- Arrowhead announces offerings of convertible senior notes and common stock
- Arrowhead Reports Promising Interim Data for Obesity RNAi Trials